Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HLX10 + HLX04 + XELOX versus placebo + bevacizumab + XELOX as first-line treatment for metastatic colorectal cancer
CTR20200692Phase 3Active
- Sponsor
- HyBioPharma
- Start
- Mar 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of serplulimab, bevacizumab, capecitabine, oxaliplatin in colorectal cancer (CRC), metastatic colorectal adenocarcinoma (mCRC), sponsored by HyBioPharma. Started Mar 2021; status: active.
02
Drugs
serplulimabbevacizumabcapecitabineoxaliplatin
03
Conditions
colorectal cancer (CRC)metastatic colorectal adenocarcinoma (mCRC)
Beyond the preview
Go deeper on CTR20200692.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20200692.